Kura Oncology, Inc. (KURA)
Stock Price:
$17.16 USD
0.23 (1.36%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
779.69M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-68.41M |
| Shares Out |
55.90M |
| EPS (ttm) |
-1.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$17.16 |
| Previous Close |
$16.93 |
| Change ($) |
0.23 |
| Change (%) |
1.36% |
| Day's Open |
16.86 |
| Day's Range |
16.72 - 17.42 |
| Day's Volume |
408,882 |
| 52-Week Range |
6.35 - 20.00 |
More Stats
| Market Cap |
779.69M |
| Enterprise Value |
570.05M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.90M |
| Float |
40.46M |
| EPS (basic) |
-1.56 |
| EPS (diluted) |
-1.56 |
| FCF / Share |
-1.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.81M |
| Short Ratio |
6.42 |
| Short % of Float |
8.70% |
| Beta |
2.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.61 |
| Revenue |
n/a |
| Operating Income |
-72.78M |
| Net Income |
-68.41M |
| Free Cash Flow |
-60.84M |
| Net Cash |
209.65M |
| Net Cash / Share |
4.61 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-22.95% |
| ROE |
-38.79% |
| ROIC |
-37.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$24.75*
(44.23% upside)
Low
22.0
Current: $17.16
High
28.0
Target: 24.75
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -67.48 | -62.88 | -36.08 | -24.54 | -19.99 |
| Net Income | -63.14 | -60.45 | -35.43 | -27.56 | -22.63 |
| Shares Outstanding | 41.95 | 35.19 | 23.24 | 18.70 | 9.93 |
| Earnings Per Share | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 |
| Operating Cash Flow | -54.76 | -48.66 | -28.44 | -25.35 | -17.93 |
| Capital Expenditures | - | - | - | - | -0.06 |
| Free Cash Flow | -54.76 | -48.66 | -28.44 | -25.35 | -17.99 |
| Cash & Equivalents | 237 | 179 | 93.15 | 67.79 | 85.75 |
| Total Debt | 7.50 | 7.50 | 7.10 | 7.32 | - |
| Net Cash / Debt | 229 | 171 | 86.05 | 60.47 | 85.75 |
| Assets | 242 | 182 | 95.85 | 69.82 | 87.26 |
| Liabilities | 23.19 | 21.39 | 15.99 | 12.95 | 5.16 |
| Book Value | 219 | 161 | 79.87 | 56.88 | 82.10 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kura Oncology, Inc. |
| Country |
United States |
| Employees |
62 |
| CEO |
Troy E. Wilson |
Stock Information
| Ticker Symbol |
KURA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KURA |
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.